Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Immune checkpoint inhibitors (CKI) such as anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agents have rapidly been established as a standard of care in advanced non-small cell lung cancer (NSCLC) patients, both in the second-line setting (nivolumab, pembrolizumab and atezolizumab) and more recently in the first-line setting. After prior approval of pembrolizumab monotherapy for NSCLC patients with tumor cell PD-L1 immunohistochemical expression ≥50 %, treatment with CKI has been introduced in the first-line strategy also for lower PD-L1 expression levels, in this case combined with standard chemotherapy (CT) [1].

Source: Lung Cancer - October 22, 2020 Category: Cancer & Oncology Authors: Melissa Bersanelli, Sebastiano Buti, Diana Giannarelli, Alessandro Leonetti, Alessio Cortellini, Giuseppe Lo Russo, Diego Signorelli, Luca Toschi, Michele Milella, Sara Pilotto, Emilio Bria, Claudia Proto, Anna Mariniello, Giovanni Randon, Sabrina Rossi, Source Type: research